Total Funding
28
30
Total FundingPost-IPO Equity raised
Growth Score
0 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
224092
Rubius has developed the technology to grow, genetically engineer and mature long-circulating Red-Cell Therapeutics.
Robert J Deans: Chief Scientific Officer
Kelly Burke: Senior Talent Acquisition PartnerPast Role: Drizzle, Co-Founder and Business Development
About the Company
Rubius Therapeutics is creating RCTs™ as a new class of medicines. Leading applications include programs in cancer, enzyme deficiency diseases and the induction of tolerance to treat autoimmune disease. The company was conceived and launched by Flagship VentureLabs®, the innovation foundry where a team of scientific entrepreneurs systematically
evolve enterprising ideas based upon previously undiscovered areas of science into real-world inventions and ventures.
